FDA Approves First Shot to Prevent HIV
Even though people at high risk for developing HIV have long been able to take daily pills to prevent infection, many of them don’t do it because of perceived stigma or challenges with accessing healthcare, paying for prescriptions, or consistently sticking with the medication regimen.Now, there’s a new option that can prevent HIV without the need for daily pills: On December 20, 2021, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release), a shot injected every two months to prevent HIV in at-risk adults and adolescents who weigh at least 77 pounds. The drug’s developer, ViiV Healthcare, said in a December 2021 statement that it would begin shipping the shot to U.S. distributors in early 2022.New Delivery Method May Mean More Compliance, Depending on Availability, Other Factors “This has…